Lymphoma
Conditions
Brief summary
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin's lymphoma and shows extremely poor survival. Several retrospective studies and singe-arm prospective phase 2 studies have shown that pegaspargase combined Gemox or CHOP regimen achieved a promising efficacy in treatment of ENKTL. However, there is no prospective study to compare the efficacy of these two regimens. This prospective pilot study to compare the efficacy and safety of the P-Gemoxd chemotherapy regimen with those of the P-CHOP regimen for stage IE to IIE ENKTL.
Detailed description
Treatment PA-Gemoxd dosages were as follows: days 1 and 5, 30-min intravenous infusion of 800 mg/m2 gemcitabine; day 1, 2-h intravenous infusion of 85 mg/m2 oxaliplatin; day 1, deep intramuscular injection of 2000 U/m2 PEG-ASP at four different sites; d1-5, intravenous infusion of 15mg dexamethasone. The regimen was repeated every 3 weeks for four cycles followed by involved-field radiotherapy after got CR, PR or SD. Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
Interventions
DRUGpegaspargase
P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four. P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four.
DRUGGemcitabine
800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
DRUGOxaliplatin
85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
DRUGDexamethasone
15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
DRUGCyclophosphamide
750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
DRUGDoxorubicin
50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
DRUGVincristine
1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
DRUGPrednisone
60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
RADIATIONIMRT
After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
Sponsors
Hunan Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. pathologically confirmed, previously untreated ENKTL with stage I/II (for stage I, the patients should have one of the following risk factors: EBV-DNA \> upper limit of normal, lesions beyond nasal, fever, LDH elevation); 2. age range from 18 to 70 years; 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 4. at least one measurable lesion; 5. adequate haematologic function (haemoglobin \> 8.0 g/l, absolute neutrophil count \> 1500/ml, platelets \> 75,000/l), 6. adequate hepatic function (total serum bilirubin ≤ 1.5 times the upper limit of normal, alanine aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper limit of normal), 7. Hepatitis B virus carriers should have normal HBV-DNA copies and should use antiviral drugs. For patients with elevated HBV-DNA, should use antiviral drugs until the HBV-DNA decrease to \< the upper limit of normal. 8. adequate renal function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50 ml/min); 9. normal coagulation function and electrocardiogram results. 10. Prior chemotherapy and radiotherapy should have been completed \>4 weeks earlier, 11. willingness to provide written informed consent.
Exclusion criteria
1. mismatch the inclusion criteria 2. systematic central nervous system involvement, previous or concomitant malignancies and any coexisting medical problems that could cause poor compliance with the study protocol. 3. primary lesion not from the upper respiratory
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate（complete remission rate + partial remission rate） | every 6 weeks,up to completion of treatment (approximately 6 months) | The criteria for the efficacy evaluation (overall response rate and complete remission) of the regimen is according to the following article: Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. |
| progression free survival | up to end of follow-up-phase (approximately 3 years) | time from the date of enrollment to date of disease progression, or death of any cause, or date of lost follow-up, whichever comes first |
| overall survival | up to end of follow-up-phase (approximately 3 years) | overall survival (OS): time from the date of enrollment to date of death from any cause, or date of lost follow-up, whichever comes first |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events according to Common Terminology Criteria for Adverse Events v3.0 | every 3 weeks,up to completion of treatment (approximately 6 months) | including hematological safety and non-hematological safety. All the adverse events will be classified according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) |
Other
| Measure | Time frame |
|---|---|
| Serum Epstein-Barr virus (EBV) DNA copies | every 3 weeks,up to completion of treatment (approximately 6 months) |
Countries
China
Outcome results
None listed